Clinical Trial Update: Study to Evaluate the Safety and Efficacy of Daily Subcutaneous Metreleptin Treatment in Subjects With PL [Phase 3]

View source ↗

Summary

A Phase 3 trial evaluating daily subcutaneous metreleptin in partial lipodystrophy, sponsored by Amryt Pharma; the study is currently ACTIVE_NOT_RECRUITING.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Partial Lipodystrophy

Drugs mentioned

• Metreleptin (metreleptin)

Snippet

Sponsor: Amryt Pharma | Conditions: Partial Lipodystrophy | Phase 3 | Status: ACTIVE_NOT_RECRUITING